SEC Form 4 · accession 0001179110-17-002818
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
AbbVie Inc.
10% Owner
Period of report
Feb 2, 2017
Accepted (ET)
Feb 21, 2017 · 5:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Feb 2, 2017 | C | 1,505,241 | — | A | 1,640,473 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Class B Common StockF1 | — | Feb 2, 2017 | C | 1,505,241 | D | Nov 22, 2016 | — | Class A Common Stock | 1,505,241 | 0 | D |
Explanation of responses
- F1The Class B common stock is convertible in Class A common stock on a one-for-one basis at the holder's election at any time after November 22, 2016. The conversion right of the Class B common stock has no expiration date.